Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cullinan TherapeuticsCGEM +7.21%22 Median PS Value is $0.00 as of Aug. 11, 2026. GuruFocus rates CGEM with a GF Score™ of 22/100. The stock has 5 warning signs investors should review. Among 275 Biotechnology companies, Cullinan Therapeutics ranks worse than 363636% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Cullinan Therapeutics's Median PS Value or its related term are showing as below:
CGEM's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.65 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Cullinan Therapeutics (NAS:CGEM) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Cullinan Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
19.66
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cullinan Therapeutics Median PS Value Related Terms
Cullinan Therapeutics Median PS Value Historical Data
* Premium members only.
The historical data trend for Cullinan Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CGEM vs VOR, ANRO, OLMA: Median PS Value Comparison
For the Biotechnology subindustry, Cullinan Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cullinan Therapeutics Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cullinan Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Cullinan Therapeutics's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is .
Cullinan Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cullinan Therapeutics (CGEM) has a Median PS Value of $0.00 as of Aug. 11, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Cullinan Therapeutics and its competitors. According to the industry distribution chart, Cullinan Therapeutics ranks #999999 out of 275 companies in the Biotechnology industry.
Is Cullinan Therapeutics' Median PS Value too high?
Cullinan Therapeutics' current Median PS Value is $0.00. Based on the distribution chart, Cullinan Therapeutics ranks #999999 out of 275 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cullinan Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Cullinan Therapeutics' Median PS Value compare to VOR and ANRO?
According to the Biotechnology industry distribution chart, Cullinan Therapeutics ranks #999999 out of 275 companies for Median PS Value. This places Cullinan Therapeutics in the lower half of its industry. The industry median Median PS Value is 0.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.65, based on 275 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Cullinan Therapeutics and its competitors. For the Biotechnology industry, the median Median PS Value is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cullinan Therapeutics's current Median PS Value is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cullinan Therapeutics stock overvalued right now?
Cullinan Therapeutics (CGEM) has a current Median PS Value of $0.00. The current Median PS Value is $0.00. Cullinan Therapeutics' overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Cullinan Therapeutics (CGEM), the current Median PS Value is $0.00 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
22GF Score
Get the complete analysis for CGEM
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGEM has been successfully added to your 
